GPE
Federal Judge Orders Trump Administration to Comply with Ruling Against Federal Funding Freeze
federal funding freeze, court order violation, Judge John McConnell, Trump administration, state attorneys general, federal grants, compliance
U.S. Hospitals Urge Trump to Exempt Medical Supplies and Pharmaceuticals from New Tariffs
Tariffs, medical supplies, pharmaceuticals, American Hospital Association, China, Mexico, Canada, healthcare costs, supply chain disruption, patient safety
Pharmaceutical Giants Bristol Myers Squibb and Kyowa Kirin Announce 119 Layoffs in New Jersey Amid Restructuring Efforts
Bristol Myers Squibb, Kyowa Kirin, layoffs, New Jersey, restructuring, pharmaceutical industry, cost-cutting, workforce reduction
Bristol Myers Squibb and Kyowa Kirin Announce New Rounds of Layoffs in New Jersey
Pharmaceutical layoffs, workforce reduction, cost-cutting measures, Bristol Myers Squibb, Kyowa Kirin, New Jersey pharma industry
Pfizer Exceeds Q4 Expectations: COVID-19 Products and Cost-Cutting Drive Strong Performance
Pfizer, Q4 earnings, COVID-19 portfolio, cost-cutting initiatives, revenue growth, Paxlovid, financial recovery, 2025 guidance
AstraZeneca Cancels £450 Million UK Vaccine Plant Expansion Amid Government Funding Reduction
AstraZeneca, vaccine manufacturing, UK investment, government funding, Labour administration, economic growth, pharmaceutical industry
Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market
Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus
Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study
Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche
New year starts with a bang as trio of venture financings brings in $382M
Venture capital, Biotech funding, Megarounds, Tenvie Therapeutics, Private financing, Life sciences investments
J&J’s Rybrevant-Lazcluze Combo Demonstrates Superior Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC
Rybrevant, Lazcluze, Tagrisso, NSCLC, EGFR mutation, overall survival, Phase III MARIPOSA trial, chemotherapy-free regimen